miR-200b is involved in intestinal fibrosis of Crohn's disease

  • Authors:
    • Yingwei Chen
    • Wensong Ge
    • Leiming Xu
    • Chunying Qu
    • Mingjie Zhu
    • Wenzhu Zhang
    • Yongtao Xiao
  • View Affiliations

  • Published online on: January 23, 2012     https://doi.org/10.3892/ijmm.2012.894
  • Pages: 601-606
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Intestinal fibrosis is one of the major serious complications of Crohn's disease (CD). However, there are no effective antifibrotic drugs to treat intestinal fibrosis in CD. Therefore, it is important to understand the pathogenesis of fibrosis in CD. It has been reported that members of the miR-200 family are essential in the regulation of renal fibrogenesis. In this study, we analyzed the function of miR-200a and miR-200b in intestinal fibrosis, which was induced by transforming growth factor β1 (TGF-β1) in vitro. Furthermore, we detected the expression of miR-200a and miR-200b in CD specimens, which were divided into groups of fibrosis and no-fibrosis. The results of this study showed that administration of miR-200b could partially protect intestinal epithelial cells from fibrogenesis in vitro. Furthermore, we found that miR-200b was overexpressed in the serum of the fibrosis group. The results suggest that miR-200b has potential value for diagnostic and therapeutic applications for CD patients with fibrosis complications.

Introduction

Fibrosis is one of major complications in Crohn’s disease (CD), which results from chronic inflammation. Severe fibrosis could result in critical narrowing of the lumen stenosis, or stricture, commonly leading to obstruction that requires surgical or mechanical intervention (13). At present, there are no approved or effective medical therapies aimed specifically at fibrosis or stricture in CD. Anti-inflammatory therapies do not prevent fibrosis nor do they reverse established strictures, which may present years after remission of active inflammation. Although this study is still limited, it can expand our understanding of cellular and molecular mechanisms leading to fibrosis in CD.

microRNAs (miRNAs) are noncoding RNAs that negatively regulate target genes expression at the post-transcriptional level. There is growing evidence to suggest that members of miR-200 family are implicated in diverse biological and pathological processes. Recent ground-breaking studies have established functional associations between miR-200 and key effectors of the epithelial-to-mesenchymal-transition (EMT) occurring in the context of carcinogenesis and embryonic development. Gregory et al (4) reported that miR-200 and miR-205 could inhibit the zinc finger E-box-binding homeobox 1 (ZEB1) and ZEB2, ZEB1 (TCF8/EF1) and ZEB2 [SMAD-interacting protein 1 (SIP1)/ZFXH1B] and thus maintain the epithelial cell phenotype (4). Oba et al (5) indicated that a miR-200b precursor could ameliorate renal tubulointerstitial fibrosis. The purpose of this study was to investigate the role of miR-200a and miR-200b in the pathogenesis of intestinal fibrosis. Initial experiments demonstrated that introduction of miR-200b in intestinal epithelial cells could partially oppose fibrosis, which was induced by transforming growth factor β1 (TGF-β1). Subsequent data showed the aberrant expression of miR-200b in serum is a potential diagnostic marker for CD patients with fibrosis complications.

Materials and methods

TGF-β1-induced fibrosis in vitro

DLD-1 was a colorectal adenocarcinoma epithelial cell line, which was cultured in DMEM (Gibco) containing 10% fetal bovine serum (FBS). DLD-1 cells were stimulated with 10 ng/ml (TGF-β1, Sigma) for 24, 48 and 72 h. The total-RNA and protein were harvested at the above-indicated times. To investigate the effect of miRNAs on fibrosis, DLD-1 cells were transfected with 50 pM miR-200a or miR-200b for 24 h using Lipofectamine RNAiMAX (Invitrogen), then stimulated with 10 ng/ml TGF-β1. After 24 h, the cells were harvested by extracting total-RNA and protein.

miRNA assays

Total-RNA was extracted from serum, tissues of patients and DLD-1 cells by using the mirVana PARIS and miRVana miRNA isolation kit (Ambion). TaqMan miRNA assay (Applied Biosystems) was used to quantify the relative expression level of miR-200a (assay ID. 000502), miR-200b (assay ID. 002251), and U6 (assay ID. 001093) was used as an internal control. cDNA was synthesized using the TaqMan miRNA Reverse Transcription kit (Applied Biosystems). The reaction was performed for 30 min at 16°C, 30 min at 42°C, and 5 min at 85°C. The LightCycler® 480 Real-Time PCR System (Roche) was used to detect miRNA expression. All reactions were run in triplicate.

Real-time PCR

The total-RNA was extracted from DLD-1 cells with TRIzol (Invitrogen) according to the protocol of manufacture. Real-time PCR was performed to measure the expression of vimentin, fibronectin, E-cadherin, fibronectin. Real-time PCR was performed with the following PCR primers: GAPDH, forward, 5′-GAAGGTGAAGGTCGGAGTC-3′ and reverse, 5′-GAAGATGGTGATGGGATTTC-3′; CDH1, forward, 5′-GGAGGAGAGCGGTGGTCAAA-3′ and reverse, 5′-TGTG CAGCTGGCTCAAGTCAA-3′; vimentin, forward, 5′-CCTC CTACCGCAGGATGTT-3′ and reverse, 5′-CTGCCCAGG CTGTAGGTG-3′; α-SMA, forward, 5′-CCGACCGAATGCA GAAGGA-3′ and reverse, 5′-ACAGAGTATTTGCGCTCCG AA-3′; fibronectin, forward, 5′AGACCATACCTGCCGAATG TAG-3′ and reverse, 5′-GAGAGCTTCCTGTCCTGTAGAG-3′; SYBR-Green Universal Master Mix kit (ABI) and High Capacity cDNA Reverse Transcription kit (ABI) were employed to detect the levels of these genes. All reactions were repeated four times and GAPDH was used to normalize the target genes.

Western blotting

Protein of 20 μg/well was separated on 4–12% SDS-polyacrylamide gels and transferred onto nitrocellulose membranes (Invitrogen) using a dry blotting system (Invitrogen). After blocking in 1X TBST, 5% nonfat dry milk, 0.2% Tween-20 at room temperature for 30 min. The membranes were incubated with the primary antibodies in blocking buffer (1X TBST, 3% nonfat dry milk, 0.2% Tween-20) overnight at 4°C. Antibodies were used at a dilution of 1:1,000. The membranes were washed three times for 30 min with 1X TBST and then incubated with secondary antibodies at a final dilution of 1:2,000. After final washes with 1X TBS, 0.2% Tween-20, the signals were detected using ECL chemiluminescence reagents (Pierce). Antibodies of N-cadherin, E-cadherin, vimentin and actin α2 smooth muscle (α-SMA) were used in this assay. To confirm that the same amount of protein was investigated, the expression of GAPDH was investigated simultaneously.

Specimen preparation

A total of 20 tissue specimens from CD patients (10 fibrosis samples and 10 no-fibrosis samples) were obtained from the Department of Pathology, Xinhua Hospital, Shanghai, China. The blood samples were donated from the above patients (Table I). All of the patients or their guardians provided written informed consent, and Faculty of Medicine’s Ethics Committee of Xinhua Hospital approved all aspects of this study.

Table I

Characteristics of Crohn’s disease patients.

Table I

Characteristics of Crohn’s disease patients.

AgeGenderDiagnosis Tissue-stainingN-cadherin stainingVimentin stainingα-SMA
Fibrosis31MCD Intestine/serum+++++++
35MCD Intestine/serum++++++
47FCD Intestine/serum+++
73FCDIntestine, colon/serum++++++
41FCDIntestine, colon/serum+++++
39FCD Intestine/serum+++++
54FCDIntestine, sigmoid/serum+++
74MCD Intestine/serum+++++++
54MCDIntestine, sigmoid/serum++++
68FCDIntestine, sigmoid/serum++++
No-fibrosis37MCDColon ascendens, intestine/serum+
49MCD Intestine/serum+
17MCDIntestine, colon/serum
24MCD Intestine/serum
27MCD Intestine/serum+
29FCD Intestine/serum
16FCD Intestine/serum
22MCD Intestine/serum
27MCDIntestine, colon/serum
24MCD Intestine/serum

[i] Crohn’s disease patients were divided into two subgroups, fibrosis and no fibrosis, according to the staining of α-smooth muscle actin (α-SMA) and vimentin, which are the two markers of fibrosis. (+, mild; ++, moderate; +++, strong).

Immunohistochemistry

Immunohistochemical studies for the expression of N-cadherin, E-cadherin, vimentin, and α-SMA were performed on 20 CD samples by using an avidin-biotin peroxidase method with diaminobenzidine (DAB) chromogen. After antigen retrieval (microwave treatment of formalin-fixed, paraffin-embedded, 40 min at 240 W in citrate buffer, pH 6.0), the tissues were blocked with bovine serum albumin (BSA). As primary antibodies, mouse monoclonal and rabbit polyclonal antibodies (N-cadherin, Novus, dilution 1:200; E-cadherin, Cell Signal Technology, dilution 1:200; vimentin, Cell Signal Technology, 1:100; α-SMA, Novus, dilution 1:200) were used in this study. After incubation for 30 min at 37°C the slides were rinsed in phosphate-buffered saline (PBS) and incubated with the secondary antibody for 2 h at room temperature. Antibody binding was visualized with 0.05% DAB and 0.01% hydrogen peroxide. The material was rinsed in PBS and counterstained with hematoxylin.

Statistical analysis

All data are presented as mean ± SD. When comparisons were made between two different groups, statistical significance was determined by the Student’s t-test using the StatView software program.

Results

Established TGF-β1-induces fibrosis in vitro

It is well accepted that TGF-β is a major inducer of fibrosis and has different isoforms. High levels of TGF-β1 have often been found in many fibrotic tissues, and have been implicated as a mediator of fibrosis in many diseases. Furthermore, TGF-β1 was firstly identified as an inducer of EMT in normal mammary epithelial cells and has since been shown to mediate EMT in a number of different epithelial cells, including renal proximal tubular and lens cells (69). Here, in order to clarify the effect of miR-200a and miR-200b on intestinal fibrosis, we initially established a TGF-β1-induced fibrotic model in vitro in a colorectal epithelial cell line (DLD-1). In this model, the DLD-1 cells were stimulated with TGF-β1 (10 ng/ml) for 24, 48 and 72 h. Real-time PCR and western blot analysis demonstrated that TGF-β1 mediated repression of E-cadherin, and induction of N-cadherin, α-SMA, fibronectin, and vimentin. E-cadherin was known to be involved in homophilic interactions between epithelial cells and was necessary for the formation of zonulae occludens. In the normal intestinal epithelial cells, E-cadherin staining was strong at the lateral cell membrane between cell contacting sites (10). However, E-cadherin expression was lost or was significantly reduced during the process of EMT. N-cadherin, which is usually expressed in mesenchymal cells and fibroblasts, has often been used to monitor the progress of EMT and fibrogenesis (11,12). Vimentin is a type III intermediate filament protein that is expressed in mesenchymal cells and fibroblasts (13,14). During the development of intestinal fibrosis in responding to chronic pressure or volume overload, fibroblasts could become activated to become myofibroblasts, which strongly express α-SMA and secrete abundant, disorganized collagen (1517). The above data indicate that TGF-β1 not only induced fibrosis, but also the EMT process. At the same time, we found that the expression of miR-200a and miR-200b were significantly inhibited by TGF-β1 (Fig. 1).

miR-200b ameliorates TGF-β1-induced fibrosis

We next investigated the role of miR-200a and miR-200b in intestinal fibrogenesis in vitro, with TGF-β1 stimulated DLD-1 cells for 24 h prior to introduction of miR-200a or miR-200b. miR-200b, but not miR-200a, increased the expression of E-cadherin and simultaneously reduced the expression of vimentin, fibronectin and N-cadherin (Fig. 2). It was thus suggested that miR-200b could ameliorate the fibrosis or EMT of intestinal epithelial cells in vitro. Recent studies have indicated that the transcriptional repressors ZEB1 (TCF8/EF1) and ZEB2 [SMAD-interacting protein 1 (SIP1)/ZFXH1B] are two direct targets of members of the miR-200 family (4). Here, real time PCR analysis showed that ZEB1 and ZEB2 were significantly inhibited by miR-200a or miR-200b (Fig. 2). These results support the notion that miR-200b could ameliorate intestinal fibrosis through downregulation of ZEB1, ZEB2.

miR-200 is related to fibrogenesis of CD

Intestinal fibrosis is a major complication of CD, but the precise mechanism is only partially understood. As a result, the exploration of specific therapies to halt fibrosis have been hindered. Here, we evaluated the possible contribution of the epithelial to mesenchymal transition (EMT) to intestinal fibrosis associated with CD. We detected the expression of specific markers of EMT and fibrosis in twenty CD specimens (10 fibrosis, and 10 no-fibrosis) by immunohistochemistry. Compared to the no-fibrosis specimens, we found that staining of N-cadherin, α-SMA and vimentin was very strong in fibrosis specimens (Fig. 3, Table I). These results prompted us to assess whether miR-200a or miR-200b are related to fibrogenesis of CD.

Serum miR-200b is a potential diagnostic marker for CD with fibrosis complications

In previous studies, Murakami et al (18) showed that overexpression of miR-200b could be connected to the progression of liver fibrosis. In order to investigate whether miR-200a or miR-200b could serve as diagnostic markers for CD fibrosis, we evaluated their expression in CD serum. We collected 10 fibrosis and 10 no-fibrosis blood samples and calculated the expression of miR-200a and miR-200b by TaqMan real-time PCR. Sixteen healthy blood samples were used as negative control. The results indicate that miR-200b increased significantly in serum of the fibrosis group when compared to that of the no-fibrosis group or from healthy individuals, (P<0.05, P<0.01). For miR-200a, we could not find a significant difference between the fibrosis and no-fibrosis groups (P>0.05) (Fig. 4).

Discussion

Intestinal fibrosis is a common complication of CD that may require surgical intervention if it became seriously symptomatic. The traditional mechanisms underlying intestinal fibrosis are associated to the presence of chronic inflammation. However, it is also possible that novel mechanisms independent of persistent immune activation exist in the gut (18,19). At present, the development of a preventive and more effective management of intestinal fibrosis is hampered by the lack of a in-depth understanding of the basic pathophysiological factors involved in it. To provide novel mechanisms for intestinal fibrosis, we revealed the association between miR-200 and intestinal fibrosis. Initially, we analyzed the role of miR-200a and miR-200b in the intestinal fibrosis in vitro. The findings indicate that miR-200b could ameliorate intestinal fibrosis that was induced by TGF-β1. Several studies have shown that the members of the miR-200 family could target ZEB1 and ZEB2 (4) directly. Here, we indicated that ZEB1 and ZEB2 decreased significantly in the presence of miR-200a or miR-200b. It was suggested that miR-200b inhibited the process of intestinal fibrosis through repressing ZEB1 and ZEB2. However, more studies are needed to investigate the exact mechanisms involved (Figs. 1 and 2).

To provide further evidence for intestinal fibrosis, we revealed the association between miR-200 expression and CD fibrosis. We divided CD samples into two groups: fibrosis and no-fibrosis. Then, we evaluated the expression of miR-200a and miR-200b in the serum of CD samples. The results showed that miR-200b was significantly elevated in the group of CD fibrosis compared to the no-fibrosis group or the healthy controls, but surprisingly, miR-200a did not increase (Fig. 4). miRNAs are usually described as highly tissue-specific biomarkers with potential clinical applicability for defining the cancer origin of metastases. Recent studies suggested that circulating miRNA has been a valuable biomarker for several diseases, including different types of cancer (2039). In this study, it was shown that expression of miR-200b increased significantly in the serum of the CD fibrosis group. This led us to hypothesize that serum miR-200b could be a candidate CD fibrosis diagnostic biomarker.

EMT is a process in which epithelial cells lose their phenotypic and functional characteristics while acquiring mesenchymal features. Although EMT is not a common event in adults, this process has been implicated in such instances as wound healing and fibrosis. The role of EMT in intestinal fibrosis has yet to be investigated. Intestinal fibrosis is thought to occur as a result of chronic inflammation and dysregulated wound healing (40,41). In this study, we demonstrated that EMT may promote intestinal fibrogenesis, which was probably inhibited by miR-200b (Figs. 3 and 5). In future studies, we will attempt to provide additional evidence to prove this hypothesis.

Acknowledgements

This study was supported by the Key Scientific Research Program of the Shanghai Health Bureau (2010005), Program for Innovative Research Team of the Shanghai Municipal Education Commission and by funding of the Xinhua Hospital (11QYJ010) and Shanghai Key Laboratory of Pediatric Gastroenterology and Nutrition (11DZ2260500). We thank Professor W. Cai for his contribution.

References

1 

JB PucilowskaKL WilliamsPK LundFibrogenesis. IV Fibrosis and inflammatory bowel disease: cellular mediators and animal modelsAm J Physiol Gastrointest Liver Physiol279G653G659200011005750

2 

F RiederC FiocchiIntestinal fibrosis in inflammatory bowel disease - current knowledge and future perspectivesJ Crohns Colitis2279290200810.1016/j.crohns.2008.05.00921172225

3 

F RiederC FiocchiIntestinal fibrosis in inflammatory bowel disease: progress in basic and clinical scienceCurr Opin Gastroenterol24462468200810.1097/MOG.0b013e3282ff8b3618622160

4 

PA GregoryAG BertEL PatersonThe miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1Nat Cell Biol10593601200810.1038/ncb172218376396

5 

S ObaS KumanoE SuzukimiR-200b precursor can ameliorate renal tubulointerstitial fibrosisPLoS One5e13614201010.1371/journal.pone.001361421049046

6 

S LamouilleR DerynckCell size and invasion in TGF-beta-induced epithelial to mesenchymal transition is regulated by activation of the mTOR pathwayJ Cell Biol178437451200710.1083/jcb.20061114617646396

7 

JJ HillTL TremblayC CantinM O’Connor-McCourtJF KellyAE LenferinkGlycoproteomic analysis of two mouse mammary cell lines during transforming growth factor (TGF)-beta induced epithelial to mesenchymal transitionProteome Sci72200910.1186/1477-5956-7-219128513

8 

AB RobertsF TianSD ByfieldSmad3 is key to TGF-beta-mediated epithelial-to-mesenchymal transition, fibrosis, tumor suppression and metastasisCytokine Growth Factor Rev171927200610.1016/j.cytogfr.2005.09.00816290023

9 

J XuS LamouilleR DerynckTGF-beta-induced epithelial to mesenchymal transitionCell Res19156172200910.1038/cr.2009.519153598

10 

K GravdalOJ HalvorsenSA HaukaasLA AkslenA switch from E-cadherin to N-cadherin expression indicates epithelial to mesenchymal transition and is of strong and independent importance for the progress of prostate cancerClin Cancer Res1370037011200710.1158/1078-0432.CCR-07-126318056176

11 

S NakajimaR DoiE ToyodaN-cadherin expression and epithelial-mesenchymal transition in pancreatic carcinomaClin Cancer Res1041254133200410.1158/1078-0432.CCR-0578-0315217949

12 

JB KimS IslamYJ KimN-Cadherin extracellular repeat 4 mediates epithelial to mesenchymal transition and increased motilityJ Cell Biol15111931206200010.1083/jcb.151.6.119311121435

13 

K VuoriluotoH HaugenS KiviluotoVimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by governing Axl expression in breast cancerOncogene3014361448201110.1038/onc.2010.50921057535

14 

J IvaskaVimentin: central hub in EMT induction?Small Gtpases25153201110.4161/sgtp.2.1.1511421686283

15 

G CarpinoS MoriniS Ginanni CorradiniAlpha-SMA expression in hepatic stellate cells and quantitative analysis of hepatic fibrosis in cirrhosis and in recurrent chronic hepatitis after liver transplantationDig Liver Dis37349356200510.1016/j.dld.2004.11.009

16 

K InaH KitamuraS TatsukawaY FujikuraSignificance of alpha-SMA in myofibroblasts emerging in renal tubulointerstitial fibrosisHistol Histopathol26855866201121630215

17 

N AkpolatS YahsiA GodekmerdanM YalnizK DemirbagThe value of alpha-SMA in the evaluation of hepatic fibrosis severity in hepatitis B infection and cirrhosis development: a histopathological and immunohistochemical studyHistopathology47276280200510.1111/j.1365-2559.2005.02226.x16115228

18 

Y MurakamiH ToyodaM TanakaThe progression of liver fibrosis is related with overexpression of the miR-199 and 200 familiesPLoS One6e16081201110.1371/journal.pone.001608121283674

19 

W Van MoerkerckeG DeboeverG LambrechtK HertveldtSevere bridging fibrosis of the colon in a man with inflammatory bowel diseaseEndoscopy39Suppl 1E294200717957610

20 

J AiR ZhangY LiCirculating microRNA-1 as a potential novel biomarker for acute myocardial infarctionBiochem Biophys Res Commun3917377201010.1016/j.bbrc.2009.11.00519896465

21 

N KosakaH IguchiT OchiyaCirculating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosisCancer Sci10120872092201010.1111/j.1349-7006.2010.01650.x20624164

22 

AM ZahmM ThayuNJ HandA HornerMB LeonardJR FriedmanCirculating microRNA is a biomarker of pediatric Crohn diseaseJ Pediatr Gastroenterol Nutr532633201110.1097/MPG.0b013e31822200cc21546856

23 

GK WangJQ ZhuJT ZhangCirculating microRNA: a novel potential biomarker for early diagnosis of acute myocardial infarction in humansEur Heart J31659666201010.1093/eurheartj/ehq01320159880

24 

R MahnLC HeukampS RogenhoferA von RueckerSC MullerJ EllingerCirculating microRNAs (miRNA) in serum of patients with prostate cancerUrology7712651266201110.1016/j.urology.2011.01.02021539977

25 

Y D’AlessandraP DevannaF LimanaCirculating microRNAs are new and sensitive biomarkers of myocardial infarctionEur Heart J3127652773201020534597

26 

SK GuptaC BangT ThumCirculating microRNAs as biomarkers and potential paracrine mediators of cardiovascular diseaseCirc Cardiovasc Genet3484488201010.1161/CIRCGENETICS.110.95836320959591

27 

KZ QuK ZhangH LiNH AfdhalM AlbitarCirculating microRNAs as biomarkers for hepatocellular carcinomaJ Clin Gastroenterol45355360201110.1097/MCG.0b013e3181f18ac221278583

28 

C RothB RackV MullerW JanniK PantelH SchwarzenbachCirculating microRNAs as blood-based markers for patients with primary and metastatic breast cancerBreast Cancer Res12R90201010.1186/bcr276621047409

29 

HM HeneghanN MillerAJ LoweryKJ SweeneyJ NewellMJ KerinCirculating microRNAs as novel minimally invasive biomarkers for breast cancerAnn Surg251499505201010.1097/SLA.0b013e3181cc939f20134314

30 

R ContuMV LatronicoG CondorelliCirculating microRNAs as potential biomarkers of coronary artery disease: a promise to be fulfilled?Circ Res107573574201010.1161/CIRCRESAHA.110.22798320814026

31 

PS MitchellRK ParkinEM KrohCirculating microRNAs as stable blood-based markers for cancer detectionProc Natl Acad Sci USA1051051310518200810.1073/pnas.080454910518663219

32 

W ZhuW QinU AtasoyER SauterCirculating microRNAs in breast cancer and healthy subjectsBMC Res Notes289200910.1186/1756-0500-2-8919454029

33 

S FichtlschererS De RosaH FoxCirculating microRNAs in patients with coronary artery diseaseCirc Res107677684201010.1161/CIRCRESAHA.109.21556620595655

34 

M TsujiuraD IchikawaS KomatsuCirculating microRNAs in plasma of patients with gastric cancersBr J Cancer10211741179201010.1038/sj.bjc.660560820234369

35 

S KomatsuD IchikawaH TakeshitaCirculating microRNAs in plasma of patients with oesophageal squamous cell carcinomaBr J Cancer105104111201110.1038/bjc.2011.19821673684

36 

Z ZuoGA CalinHM de PaulaCirculating microRNAs let-7a and miR-16 predict progression-free survival and overall survival in patients with myelodysplastic syndromeBlood118413415201110.1182/blood-2011-01-33070421602527

37 

J XuC WuX CheCirculating microRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitisMol Carcinog50136142201110.1002/mc.2071221229610

38 

T SukataK SumidaM KushidaCirculating microRNAs, possible indicators of progress of rat hepatocarcinogenesis from early stagesToxicol Lett2004652201110.1016/j.toxlet.2010.10.01321035526

39 

K WangS ZhangB MarzolfCirculating microRNAs, potential biomarkers for drug-induced liver injuryProc Natl Acad Sci USA10644024407200910.1073/pnas.081337110619246379

40 

JM Lopez-NovoaMA NietoInflammation and EMT: an alliance towards organ fibrosis and cancer progressionEMBO Mol Med1303314200910.1002/emmm.20090004320049734

41 

PK LundCC ZunigaIntestinal fibrosis in human and experimental inflammatory bowel diseaseCurr Opin Gastroenterol17318323200110.1097/00001574-200107000-0000417031177

Related Articles

Journal Cover

April 2012
Volume 29 Issue 4

Print ISSN: 1107-3756
Online ISSN:1791-244X

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Chen Y, Ge W, Xu L, Qu C, Zhu M, Zhang W and Xiao Y: miR-200b is involved in intestinal fibrosis of Crohn's disease. Int J Mol Med 29: 601-606, 2012
APA
Chen, Y., Ge, W., Xu, L., Qu, C., Zhu, M., Zhang, W., & Xiao, Y. (2012). miR-200b is involved in intestinal fibrosis of Crohn's disease. International Journal of Molecular Medicine, 29, 601-606. https://doi.org/10.3892/ijmm.2012.894
MLA
Chen, Y., Ge, W., Xu, L., Qu, C., Zhu, M., Zhang, W., Xiao, Y."miR-200b is involved in intestinal fibrosis of Crohn's disease". International Journal of Molecular Medicine 29.4 (2012): 601-606.
Chicago
Chen, Y., Ge, W., Xu, L., Qu, C., Zhu, M., Zhang, W., Xiao, Y."miR-200b is involved in intestinal fibrosis of Crohn's disease". International Journal of Molecular Medicine 29, no. 4 (2012): 601-606. https://doi.org/10.3892/ijmm.2012.894